Glioblastoma multiforme (GBM) is a highly aggressive, complex, and devastating form of brain cancer, effecting hundreds of people each day. We believe it is our duty to accelerate progress against this disease so we launched the Defeat GBM Research Collaborative in 2013 with the intent to double the 5 year survival rate of GBM patients. This comes at a time when collaboration is becoming the norm and the abundance of genomic data is accelerating diagnostic, prognostic, and therapeutic progress.
Oligo Research Fund
Oligodendroglioma (oligo) is a relatively rare brain tumor representing about 6% of gliomas, with a diagnosis rate of about 1,150 patients a year in the U.S. alone. Critical research is required to deliver oligo patients new therapies that are more durable and extend their lives. In order to make effective, targeted therapies a reality it is essential to identify and understand the molecular drivers of the tumor’s genesis and maintenance, as well as resistance.
Our new pediatric initiative, Project Impact, will leverage increases in knowledge gained from earlier funded research efforts, and develop a program that can address critical barriers to progress within the drug discovery and development pipeline through an integrated approach to advance research toward new treatments for pediatric brain tumor patients.
The Community Research Fund allows contributors to pool donations to support research on a specific type of tumor. This program leverages a team of highly experienced, nationally-recognized scientific experts, working with National Brain Tumor Society staff, to determine the best investment strategy for each fund.